State Street Holds 4.8% Of REGENXBIO As Gene-Therapy Milestones Approach

The passive holding comes with trial results expected this quarter and a Duchenne gene-therapy approval application planned for 2027.

Share
State Street Holds 4.8% Of REGENXBIO As Gene-Therapy Milestones Approach

State Street reported a 4.8% passive stake in REGENXBIO, a clinical-stage developer of one-time gene therapies, in a Tuesday SEC ownership disclosure. The position covers 3,153,366 common shares as of September 30, with the company approaching late-stage trial results and a planned FDA approval application.

A Passive Position, Not A Control Bid

State Street certified that its investment arose from ordinary business activity and that it does not hold the shares to change or influence REGENXBIO's control. It reported shared voting authority over 3,081,970 shares and no sole voting authority.

REGENXBIO had a market capitalization of $534 million in Tuesday trading as of 10:03 a.m. ET.

Cash Supports The Development Calendar

REGENXBIO reported third-quarter revenue of $9.2 million, against Mizuho's estimate of $5.9 million. Mizuho maintained its Outperform rating and lifted its price target to $18.00 from $7.71.

The company had $251 million in cash in the third quarter and expects its funding to last into late 2027. It has positive late-stage data for RGX-202, its Duchenne muscular dystrophy candidate, and is seeking accelerated approval.

Retinal And Duchenne Programs Near Milestones

REGENXBIO's therapies use AAV vectors — non-replicating viruses that deliver genetic material — from its NAV Technology Platform. Its own pipeline targets retinal, neuromuscular and neurodegenerative diseases, and it manufactures therapies at its facility in Rockville, Maryland.

The company is developing sura-vec with AbbVie for wet age-related macular degeneration and diabetic retinopathy. Its programs with Nippon Shinyaku, RGX-121 and RGX-111, target the lysosomal storage disorders MPS II and MPS I. REGENXBIO also sublicenses its vectors to other developers, including Novartis, whose spinal muscular atrophy treatments Zolgensma and Itvisma use the platform.

REGENXBIO expects late-stage sura-vec results for wet age-related macular degeneration in the fourth quarter of 2026. It plans to submit its RGX-202 FDA approval application in the first quarter of 2027.

Those development milestones fall within the funding window REGENXBIO expects to extend into late 2027.

Sources

More on REGENXBIO

All REGENXBIO (RGNX) coverage →